5,5-dimethyl-1-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione | 733808-35-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5,5-dimethyl-1-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione
• 英文别名: 5,5-Dimethyl-1-(pyridin-4-ylmethyl)-3-(4-(trifluoromethylthio)phenyl)imidazolidine-2,4-dione；5,5-dimethyl-1-(pyridin-4-ylmethyl)-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione
• CAS: 733808-35-0
• 化学式: C₁₈H₁₆F₃N₃O₂S
• 分子量: 395.405
• InChiKey: VZTJDCKYPWZRFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  78.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-三氟甲基硫代苯基异氰酸酯 在 sodium hydride 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 5,5-dimethyl-1-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione
  参考文献：
  名称：

  发现首批非ATP竞争性IGF-1R激酶抑制剂：与竞争性抑制剂相比的优势

  摘要：

  从源自HTS的铅中鉴定了一系列与乙内酰脲相关的IGF-1R抑制剂。它们的非竞争性质以及缓慢的结合特性为一系列化合物提供了独特的选择性和出色的细胞活性。

  DOI：

  10.1016/j.bmcl.2011.03.003

文献信息

• Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
  申请人：AVENTIS PHARMA S.A.

  公开号：US20040248884A1

  公开（公告）日：2004-12-09

  The present invention relates to a cyclic urea compound of formula I: 1 as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

  本发明涉及一种如下式的环脲化合物： 1 如本文所定义。该发明还涉及其制备方法，包括它的药物组合物以及其作为蛋白激酶抑制剂的药用，因此，它对于预防或治疗能够通过抑制蛋白激酶活性而调节的生理紊乱是有用的，比如固体肿瘤。
• Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
  申请人：PATEK Marcel

  公开号：US20080108654A1

  公开（公告）日：2008-05-08

  The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

  本公开涉及一种公式I的环状脲化合物，如此定义，以及其制备过程，包含该化合物的制药组合物和其作为蛋白激酶抑制剂的药物用途。因此，公式I的化合物对于预防或治疗能够通过抑制蛋白激酶活性调节的生理紊乱，如实体肿瘤，是有用的。
• Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors
  申请人：Strobel Hartmut

  公开号：US20080004300A1

  公开（公告）日：2008-01-03

  The invention relates to compounds of formula (I): in which R1, R2, L 1 , X, R3, A, R4, R 4 ′, R 4 ″, R 4 ″′, R5, Y and L 2 are as herein defined, salts and prodrugs thereof, to their use as protein kinase inhibitors, and to methods of treating diseases comprising adminstration thereof.

  本发明涉及以下式(I)的化合物： 其中R1、R2、L1、X、R3、A、R4、R4'、R4"、R4"'、R5、Y和L2如本文所定义，以及其盐和前药，用作蛋白激酶抑制剂，并用于治疗包括其在内的疾病的治疗方法。
• DERIVES D'UREE CYCLIQUE, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE COMME INHIBITEURS DE KINASES
  申请人：Aventis Pharma S.A.

  公开号：EP1599464A2

  公开（公告）日：2005-11-30
• NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS
  申请人：Aventis Pharma S.A.

  公开号：EP1773808B1

  公开（公告）日：2011-02-16